ID   PDK3_HUMAN              Reviewed;         406 AA.
AC   Q15120; B4DXG6;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 207.
DE   RecName: Full=[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial;
DE            EC=2.7.11.2;
DE   AltName: Full=Pyruvate dehydrogenase kinase isoform 3;
DE   Flags: Precursor;
GN   Name=PDK3; Synonyms=PDHK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7499431; DOI=10.1074/jbc.270.48.28989;
RA   Gudi R., Bowker-Kinley M.M., Kedishvili N.Y., Zhao Y., Popov K.M.;
RT   "Diversity of the pyruvate dehydrogenase kinase gene family in humans.";
RL   J. Biol. Chem. 270:28989-28994(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   CATALYTIC ACTIVITY, FUNCTION, INTERACTION WITH DLAT, AND ACTIVITY
RP   REGULATION.
RX   PubMed=10748134; DOI=10.1074/jbc.m909488199;
RA   Baker J.C., Yan X., Peng T., Kasten S., Roche T.E.;
RT   "Marked differences between two isoforms of human pyruvate dehydrogenase
RT   kinase.";
RL   J. Biol. Chem. 275:15773-15781(2000).
RN   [6]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=11486000; DOI=10.1074/jbc.m103069200;
RA   Korotchkina L.G., Patel M.S.;
RT   "Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward
RT   the three phosphorylation sites of human pyruvate dehydrogenase.";
RL   J. Biol. Chem. 276:37223-37229(2001).
RN   [7]
RP   INTERACTION WITH DLAT.
RX   PubMed=11978179; DOI=10.1042/bj20020301;
RA   Tuganova A., Boulatnikov I., Popov K.M.;
RT   "Interaction between the individual isoenzymes of pyruvate dehydrogenase
RT   kinase and the inner lipoyl-bearing domain of transacetylase component of
RT   pyruvate dehydrogenase complex.";
RL   Biochem. J. 366:129-136(2002).
RN   [8]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=16436377; DOI=10.1074/jbc.m511481200;
RA   Korotchkina L.G., Sidhu S., Patel M.S.;
RT   "Characterization of testis-specific isoenzyme of human pyruvate
RT   dehydrogenase.";
RL   J. Biol. Chem. 281:9688-9696(2006).
RN   [9]
RP   INDUCTION BY PPARD.
RX   PubMed=17669420; DOI=10.1016/j.jmb.2007.06.091;
RA   Degenhardt T., Saramaki A., Malinen M., Rieck M., Vaisanen S., Huotari A.,
RA   Herzig K.H., Muller R., Carlberg C.;
RT   "Three members of the human pyruvate dehydrogenase kinase gene family are
RT   direct targets of the peroxisome proliferator-activated receptor
RT   beta/delta.";
RL   J. Mol. Biol. 372:341-355(2007).
RN   [10]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=18718909; DOI=10.1074/jbc.m803508200;
RA   Lu C.W., Lin S.C., Chen K.F., Lai Y.Y., Tsai S.J.;
RT   "Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1
RT   promotes metabolic switch and drug resistance.";
RL   J. Biol. Chem. 283:28106-28114(2008).
RN   [11]
RP   INDUCTION.
RX   PubMed=20715114; DOI=10.1002/ijc.25599;
RA   Blouin J.M., Penot G., Collinet M., Nacfer M., Forest C., Laurent-Puig P.,
RA   Coumoul X., Barouki R., Benelli C., Bortoli S.;
RT   "Butyrate elicits a metabolic switch in human colon cancer cells by
RT   targeting the pyruvate dehydrogenase complex.";
RL   Int. J. Cancer 128:2591-2601(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   FUNCTION.
RX   PubMed=22865452; DOI=10.1158/0008-5472.can-12-0979;
RA   Kluza J., Corazao-Rozas P., Touil Y., Jendoubi M., Maire C., Guerreschi P.,
RA   Jonneaux A., Ballot C., Balayssac S., Valable S., Corroyer-Dulmont A.,
RA   Bernaudin M., Malet-Martino M., de Lassalle E.M., Maboudou P.,
RA   Formstecher P., Polakowska R., Mortier L., Marchetti P.;
RT   "Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward
RT   mitochondrial oxidative metabolism and potentiates the therapeutic activity
RT   of pro-oxidants.";
RL   Cancer Res. 72:5035-5047(2012).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 9-406 IN COMPLEX WITH ATP,
RP   FUNCTION, AND INTERACTION WITH DLAT.
RX   PubMed=15861126; DOI=10.1038/sj.emboj.7600663;
RA   Kato M., Chuang J.L., Tso S.C., Wynn R.M., Chuang D.T.;
RT   "Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl
RT   domain 2 of human pyruvate dehydrogenase complex.";
RL   EMBO J. 24:1763-1774(2005).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 9-406, AND INTERACTION WITH DLAT.
RX   PubMed=17532006; DOI=10.1016/j.jmb.2007.04.083;
RA   Devedjiev Y., Steussy C.N., Vassylyev D.G.;
RT   "Crystal structure of an asymmetric complex of pyruvate dehydrogenase
RT   kinase 3 with lipoyl domain 2 and its biological implications.";
RL   J. Mol. Biol. 370:407-416(2007).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 9-406 IN COMPLEX WITH THE
RP   INHIBITOR RADICICOL, FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH
RP   DLAT.
RX   PubMed=17683942; DOI=10.1016/j.str.2007.07.001;
RA   Kato M., Li J., Chuang J.L., Chuang D.T.;
RT   "Distinct structural mechanisms for inhibition of pyruvate dehydrogenase
RT   kinase isoforms by AZD7545, dichloroacetate, and radicicol.";
RL   Structure 15:992-1004(2007).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-219.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [19]
RP   VARIANT CMTX6 HIS-158, VARIANTS THR-114 AND SER-334, CHARACTERIZATION OF
RP   VARIANT CMTX6 HIS-158, TISSUE SPECIFICITY, AND MUTAGENESIS OF ASN-120 AND
RP   ASP-121.
RX   PubMed=23297365; DOI=10.1093/hmg/dds557;
RA   Kennerson M.L., Yiu E.M., Chuang D.T., Kidambi A., Tso S.C., Ly C.,
RA   Chaudhry R., Drew A.P., Rance G., Delatycki M.B., Zuchner S., Ryan M.M.,
RA   Nicholson G.A.;
RT   "A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is
RT   caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3)
RT   gene.";
RL   Hum. Mol. Genet. 22:1404-1416(2013).
CC   -!- FUNCTION: Inhibits pyruvate dehydrogenase activity by phosphorylation
CC       of the E1 subunit PDHA1, and thereby regulates glucose metabolism and
CC       aerobic respiration. Can also phosphorylate PDHA2. Decreases glucose
CC       utilization and increases fat metabolism in response to prolonged
CC       fasting, and as adaptation to a high-fat diet. Plays a role in glucose
CC       homeostasis and in maintaining normal blood glucose levels in function
CC       of nutrient levels and under starvation. Plays a role in the generation
CC       of reactive oxygen species. {ECO:0000269|PubMed:10748134,
CC       ECO:0000269|PubMed:11486000, ECO:0000269|PubMed:15861126,
CC       ECO:0000269|PubMed:16436377, ECO:0000269|PubMed:17683942,
CC       ECO:0000269|PubMed:18718909, ECO:0000269|PubMed:22865452}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[pyruvate dehydrogenase E1 alpha subunit] = ADP
CC         + H(+) + O-phospho-L-seryl-[pyruvate dehydrogenase E1 alpha subunit];
CC         Xref=Rhea:RHEA:23052, Rhea:RHEA-COMP:13689, Rhea:RHEA-COMP:13690,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.2;
CC         Evidence={ECO:0000269|PubMed:10748134, ECO:0000269|PubMed:11486000,
CC         ECO:0000269|PubMed:16436377};
CC   -!- ACTIVITY REGULATION: Activated by interaction with DLAT. Inhibited by
CC       AZD7545, dichloroacetate and radicicol. {ECO:0000269|PubMed:10748134,
CC       ECO:0000269|PubMed:17683942}.
CC   -!- SUBUNIT: Homodimer. Interacts with the pyruvate dehydrogenase complex
CC       subunit DLAT, and is part of the multimeric pyruvate dehydrogenase
CC       complex that contains multiple copies of pyruvate dehydrogenase (E1),
CC       dihydrolipoamide acetyltransferase (DLAT, E2) and lipoamide
CC       dehydrogenase (DLD, E3). {ECO:0000269|PubMed:10748134,
CC       ECO:0000269|PubMed:11978179, ECO:0000269|PubMed:15861126,
CC       ECO:0000269|PubMed:17532006, ECO:0000269|PubMed:17683942}.
CC   -!- INTERACTION:
CC       Q15120; P10515: DLAT; NbExp=2; IntAct=EBI-1383915, EBI-2959723;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15120-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15120-2; Sequence=VSP_043365;
CC   -!- TISSUE SPECIFICITY: Expressed in heart, skeletal muscle, spinal cord,
CC       as well as fetal and adult brain. {ECO:0000269|PubMed:23297365}.
CC   -!- INDUCTION: Up-regulated in response to hypoxia. Up-regulated in
CC       response to fatty acids. Up-regulated by PPARD.
CC       {ECO:0000269|PubMed:17669420, ECO:0000269|PubMed:18718909,
CC       ECO:0000269|PubMed:20715114}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, X-linked dominant, 6 (CMTX6)
CC       [MIM:300905]: A form of Charcot-Marie-Tooth disease, a disorder of the
CC       peripheral nervous system, characterized by progressive weakness and
CC       atrophy, initially of the peroneal muscles and later of the distal
CC       muscles of the arms. Charcot-Marie-Tooth disease is classified in two
CC       main groups on the basis of electrophysiologic properties and
CC       histopathology: primary peripheral demyelinating neuropathies
CC       characterized by severely reduced motor nerve conduction velocities
CC       (NCVs) (less than 38m/s) and segmental demyelination and remyelination,
CC       and primary peripheral axonal neuropathies characterized by normal or
CC       mildly reduced NCVs and chronic axonal degeneration and regeneration on
CC       nerve biopsy. {ECO:0000269|PubMed:23297365}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PDK/BCKDK protein kinase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L42452; AAC42011.1; -; mRNA.
DR   EMBL; AK301965; BAG63378.1; -; mRNA.
DR   EMBL; CH471074; EAW99019.1; -; Genomic_DNA.
DR   EMBL; BC015948; AAH15948.1; -; mRNA.
DR   CCDS; CCDS14212.1; -. [Q15120-1]
DR   CCDS; CCDS48088.1; -. [Q15120-2]
DR   PIR; I70160; I70160.
DR   RefSeq; NP_001135858.1; NM_001142386.2. [Q15120-2]
DR   RefSeq; NP_005382.1; NM_005391.4. [Q15120-1]
DR   PDB; 1Y8N; X-ray; 2.60 A; A=9-406.
DR   PDB; 1Y8O; X-ray; 2.48 A; A=9-406.
DR   PDB; 1Y8P; X-ray; 2.63 A; A=9-406.
DR   PDB; 2PNR; X-ray; 2.50 A; A/B/E/F=9-406.
DR   PDB; 2Q8I; X-ray; 2.60 A; A=9-406.
DR   PDBsum; 1Y8N; -.
DR   PDBsum; 1Y8O; -.
DR   PDBsum; 1Y8P; -.
DR   PDBsum; 2PNR; -.
DR   PDBsum; 2Q8I; -.
DR   AlphaFoldDB; Q15120; -.
DR   SMR; Q15120; -.
DR   BioGRID; 111191; 108.
DR   DIP; DIP-29498N; -.
DR   IntAct; Q15120; 57.
DR   MINT; Q15120; -.
DR   STRING; 9606.ENSP00000387536; -.
DR   BindingDB; Q15120; -.
DR   ChEMBL; CHEMBL3893; -.
DR   DrugBank; DB03760; Dihydrolipoic Acid.
DR   DrugBank; DB03758; Radicicol.
DR   DrugCentral; Q15120; -.
DR   GuidetoPHARMACOLOGY; 2143; -.
DR   iPTMnet; Q15120; -.
DR   PhosphoSitePlus; Q15120; -.
DR   BioMuta; PDK3; -.
DR   DMDM; 3183119; -.
DR   EPD; Q15120; -.
DR   jPOST; Q15120; -.
DR   MassIVE; Q15120; -.
DR   MaxQB; Q15120; -.
DR   PaxDb; Q15120; -.
DR   PeptideAtlas; Q15120; -.
DR   PRIDE; Q15120; -.
DR   ProteomicsDB; 60447; -. [Q15120-1]
DR   ProteomicsDB; 60448; -. [Q15120-2]
DR   Antibodypedia; 24576; 318 antibodies from 29 providers.
DR   DNASU; 5165; -.
DR   Ensembl; ENST00000379162.9; ENSP00000368460.4; ENSG00000067992.17. [Q15120-1]
DR   Ensembl; ENST00000568479.2; ENSP00000498864.1; ENSG00000067992.17. [Q15120-2]
DR   Ensembl; ENST00000648777.1; ENSP00000497727.1; ENSG00000067992.17. [Q15120-1]
DR   GeneID; 5165; -.
DR   KEGG; hsa:5165; -.
DR   MANE-Select; ENST00000379162.9; ENSP00000368460.4; NM_005391.5; NP_005382.1.
DR   UCSC; uc004dbg.4; human. [Q15120-1]
DR   CTD; 5165; -.
DR   DisGeNET; 5165; -.
DR   GeneCards; PDK3; -.
DR   GeneReviews; PDK3; -.
DR   HGNC; HGNC:8811; PDK3.
DR   HPA; ENSG00000067992; Low tissue specificity.
DR   MalaCards; PDK3; -.
DR   MIM; 300905; phenotype.
DR   MIM; 300906; gene.
DR   neXtProt; NX_Q15120; -.
DR   OpenTargets; ENSG00000067992; -.
DR   Orphanet; 352675; X-linked Charcot-Marie-Tooth disease type 6.
DR   PharmGKB; PA33156; -.
DR   VEuPathDB; HostDB:ENSG00000067992; -.
DR   eggNOG; KOG0787; Eukaryota.
DR   GeneTree; ENSGT01030000234646; -.
DR   HOGENOM; CLU_023861_1_1_1; -.
DR   InParanoid; Q15120; -.
DR   OMA; ITLNHIG; -.
DR   OrthoDB; 1242599at2759; -.
DR   PhylomeDB; Q15120; -.
DR   TreeFam; TF314918; -.
DR   BRENDA; 2.7.11.2; 2681.
DR   PathwayCommons; Q15120; -.
DR   Reactome; R-HSA-204174; Regulation of pyruvate dehydrogenase (PDH) complex.
DR   Reactome; R-HSA-5362517; Signaling by Retinoic Acid.
DR   SignaLink; Q15120; -.
DR   SIGNOR; Q15120; -.
DR   BioGRID-ORCS; 5165; 13 hits in 742 CRISPR screens.
DR   ChiTaRS; PDK3; human.
DR   EvolutionaryTrace; Q15120; -.
DR   GeneWiki; PDK3; -.
DR   GenomeRNAi; 5165; -.
DR   Pharos; Q15120; Tchem.
DR   PRO; PR:Q15120; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q15120; protein.
DR   Bgee; ENSG00000067992; Expressed in middle temporal gyrus and 190 other tissues.
DR   Genevisible; Q15120; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004740; F:pyruvate dehydrogenase (acetyl-transferring) kinase activity; IDA:UniProtKB.
DR   GO; GO:0071398; P:cellular response to fatty acid; IMP:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0097411; P:hypoxia-inducible factor-1alpha signaling pathway; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0035357; P:peroxisome proliferator activated receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0010510; P:regulation of acetyl-CoA biosynthetic process from pyruvate; IMP:UniProtKB.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; IMP:UniProtKB.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IMP:UniProtKB.
DR   Gene3D; 1.20.140.20; -; 1.
DR   Gene3D; 3.30.565.10; -; 1.
DR   InterPro; IPR036784; AK/P_DHK_N_sf.
DR   InterPro; IPR018955; BCDHK/PDK_N.
DR   InterPro; IPR039028; BCKD/PDK.
DR   InterPro; IPR003594; HATPase_C.
DR   InterPro; IPR036890; HATPase_C_sf.
DR   InterPro; IPR005467; His_kinase_dom.
DR   PANTHER; PTHR11947; PTHR11947; 1.
DR   Pfam; PF10436; BCDHK_Adom3; 1.
DR   Pfam; PF02518; HATPase_c; 1.
DR   SMART; SM00387; HATPase_c; 1.
DR   SUPFAM; SSF55874; SSF55874; 1.
DR   SUPFAM; SSF69012; SSF69012; 1.
DR   PROSITE; PS50109; HIS_KIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Carbohydrate metabolism;
KW   Charcot-Marie-Tooth disease; Disease variant; Glucose metabolism; Kinase;
KW   Mitochondrion; Neurodegeneration; Neuropathy; Nucleotide-binding;
KW   Reference proteome; Transferase; Transit peptide.
FT   TRANSIT         1..?
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000255"
FT   CHAIN           ?..406
FT                   /note="[Pyruvate dehydrogenase (acetyl-transferring)]
FT                   kinase isozyme 3, mitochondrial"
FT                   /id="PRO_0000023443"
FT   DOMAIN          131..362
FT                   /note="Histidine kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00107"
FT   REGION          383..406
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         247..254
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:15861126"
FT   BINDING         287
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:15861126"
FT   BINDING         306..307
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:15861126"
FT   BINDING         323..328
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:15861126"
FT   MOD_RES         278
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q922H2"
FT   VAR_SEQ         406
FT                   /note="Q -> QDKIKTNRTF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043365"
FT   VARIANT         114
FT                   /note="K -> T (in dbSNP:rs146331370)"
FT                   /evidence="ECO:0000269|PubMed:23297365"
FT                   /id="VAR_070081"
FT   VARIANT         158
FT                   /note="R -> H (in CMTX6; gain of function; results in a
FT                   5-fold increase in kinase activity, decreased sensitivity
FT                   to pyruvate inhibition, reduced affinity for nucleotides
FT                   and increased affinity for pyruvate dehydrogenase complex
FT                   component E2 (PDC-E2), leading to PDC hyperphosphorylation
FT                   and increased inactivation; dbSNP:rs397515323)"
FT                   /evidence="ECO:0000269|PubMed:23297365"
FT                   /id="VAR_070082"
FT   VARIANT         219
FT                   /note="E -> A (in a head & neck squamous cell carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042297"
FT   VARIANT         334
FT                   /note="Y -> S"
FT                   /evidence="ECO:0000269|PubMed:23297365"
FT                   /id="VAR_070083"
FT   MUTAGEN         120
FT                   /note="N->H: No effect on kinase activity; when associated
FT                   with N-121."
FT                   /evidence="ECO:0000269|PubMed:23297365"
FT   MUTAGEN         121
FT                   /note="D->N: No effect on kinase activity; when associated
FT                   with H-120."
FT                   /evidence="ECO:0000269|PubMed:23297365"
FT   HELIX           14..21
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           29..38
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           42..64
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           69..72
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           75..92
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           93..96
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          99..101
FT                   /evidence="ECO:0007829|PDB:2Q8I"
FT   HELIX           102..118
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           119..121
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           122..137
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           141..172
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          179..184
FT                   /evidence="ECO:0007829|PDB:2PNR"
FT   STRAND          187..192
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           193..212
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          218..224
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          233..236
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           238..260
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          262..265
FT                   /evidence="ECO:0007829|PDB:2PNR"
FT   STRAND          270..276
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          278..287
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           294..297
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           298..301
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   TURN            303..305
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:1Y8P"
FT   HELIX           327..337
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          341..347
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   TURN            348..350
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          351..360
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           362..364
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   HELIX           374..380
FT                   /evidence="ECO:0007829|PDB:1Y8O"
SQ   SEQUENCE   406 AA;  46939 MW;  EF2415D3F9D8D61E CRC64;
     MRLFRWLLKQ PVPKQIERYS RFSPSPLSIK QFLDFGRDNA CEKTSYMFLR KELPVRLANT
     MREVNLLPDN LLNRPSVGLV QSWYMQSFLE LLEYENKSPE DPQVLDNFLQ VLIKVRNRHN
     DVVPTMAQGV IEYKEKFGFD PFISTNIQYF LDRFYTNRIS FRMLINQHTL LFGGDTNPVH
     PKHIGSIDPT CNVADVVKDA YETAKMLCEQ YYLVAPELEV EEFNAKAPDK PIQVVYVPSH
     LFHMLFELFK NSMRATVELY EDRKEGYPAV KTLVTLGKED LSIKISDLGG GVPLRKIDRL
     FNYMYSTAPR PSLEPTRAAP LAGFGYGLPI SRLYARYFQG DLKLYSMEGV GTDAVIYLKA
     LSSESFERLP VFNKSAWRHY KTTPEADDWS NPSSEPRDAS KYKAKQ
//
